



Innovative back microsurgery

Press release

Top-3-ranked THE SPINE JOURNAL publishes a new study proving the excellent performance of the SpineJack®

This new biomechanical study measures the anatomical restoration of vertebrae with the SpineJack® compared to balloon kyphoplasty

Toulouse, December 2nd, 2013 - VEXIM (FR0011072602 - ALVXM), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, announces today that the results of a new comparative biomechanical study carried out by Marburg University's Traumatology Department (Germany) have been published in THE SPINE JOURNAL.

As in the first biomechanical study published (results disclosed on September 12th, 2013), the aim of this new study was to evaluate the anatomic restoration of 24 fractured vertebral bodies with osteoporosis by comparing the SpineJack® and balloon kyphoplasty techniques. The results once again demonstrated a significant difference in favor of the SpineJack® regarding the restoration of vertebral height that is achieved to reestablish spinal balance.

"The central vertebral height restoration was close to 96% for the groups treated with SpineJack®. The clinical implications include better restoration of the sagittal balance of the spine and a reduction of the kyphotic deformity", said Dr. Antonio Krüger, Orthopedic Trauma surgeon in trauma and reconstructive surgery at the Philipp's University (Marburg) and the study's main investigator.

The article, entitled "Height restoration of osteoporotic vertebral compression fractures using different intravertebral reduction devices: a cadaveric study", is available online at: <http://www.thespinejournalonline.com/article/S1529-9430%2813%2901216-3/abstract>.

Vincent Gardès, CEO of VEXIM, concludes: *"We are proud of the publication of Dr. Krüger's new study in such a prestigious clinical and scientific review as The Spine Journal, and would like to congratulate his team for their in-depth scientific work. The results of our biomechanical studies, combined with those announced recently on two other clinical studies, clearly show the efficiency of the SpineJack® and reinforce our confidence in our ability to establish it as a benchmark for the treatment of vertebral compression fractures."*

These vertebral fractures stand for 1.4 million new cases every year in Europe¹ and 700,000 in the United States².

¹ Felsenberg et al.2002

² International Osteoporosis Foundation

About The Spine Journal

The Spine Journal, the official journal of the North American Spine Society, is an international and multidisciplinary journal that publishes original, peer-reviewed articles on research and treatment related to the spine and spine care, including basic science and clinical investigations. The journal is ranked 3rd out of 63 in the Orthopedics category by Impact Factor (3.355).

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital³ and Banexi Venture, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack[®], a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 50 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. VEXIM has been listed on NYSE Alternext Paris since May 3rd 2012. For further information, please go to www.vexim.com

SpineJack^{®4}, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack[®] lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack[®] range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack[®] technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.

Contacts

VEXIM

Vincent Gardès

CEO

Tel: +33 5 61 48 48 38

shareholders@vexim.com

NewCap.

Financial Communications
and Investor Relations

Dusan Oresansky /

Emmanuel Huynh

Tel: +33 1 44 71 94 92

vexim@newcap.fr

Alize RP

Press Relations

Caroline Carmagnol

caroline@alizerp.com

Tel: +33 6 64 18 99 59

Christian Berg

christian@alizerp.com

Tel: +33 1 70 22 53 86



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM

³ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.

⁴ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.